Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Allergan Pre Actavis
Evaluate
June 17, 2015
Synergy relaxes with positive constipation data
June 17, 2015
Allergan’s $2bn Kythera takeout is a short sharp shock
January 30, 2015
He who would Valeant be
January 07, 2015
2014 another growth year as big cap stocks hold up
November 18, 2014
Allergan gets its happyish ending
November 07, 2014
Salix ruins its reputation with disastrous inventory admissions
November 03, 2014
Molecular Partners’ second try at floating in Europe’s tepid waters
October 16, 2014
Shabbvie is dead; long live Shire
October 15, 2014
Shabbvie marks difference between great and exceptional deal quarter
October 15, 2014
AbbVie-Shire pact wobbles as inversion backlash spreads
October 03, 2014
Nine months into 2014, big drug stocks post strong performance
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics